Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
This clinical research laboratory provides science, education and training in the field of immunogenicity. Autoimmune and inflammatory diseases are the primary focus. They aim at translating research about immunological reactions against biopharmaceutical treatments in patients with chronic inflammatory diseases to clinical practice.
To this end they independently test different methods for ADA detection, validate methods for detection of immune complexes by using the biobanks available at Karolinska University Hospital and the Swedish high quality patients registers. The aim is to provide clinically relevant algorithms for which patients to test, when to test them, with what methods and how to interpret the test results. Since 2003, the lab has been providing routine ADA tests for interferon beta treatment in MS patients, then ADA against natalizumab and from 2017 ADA against rituximab and ADA in immune complexes formed with infliximab. They have been part of the ABIRISK project where the lab, together with other academic and EFPIA partners, studied immunogenicity (http://www.abirisk.eu/).
The main diseases researched in the lab are autoimmune and inflammatory diseases:
- Multiple sclerosis
- Rheumatoid arthritis
- Systemic lupus erythematosus (SLE)
- ADA analysis against rituximab (Mabthera or Rituxan) with ECL on MSD platform
- Measure ADA against infliximab with PandA assay
- Analyse neutralising antibodies against IFNβ adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade) with iLite bioassay
- Measure ADA against natalizumab with ELISA
Website link: https://ki.se/cns/ada-lab-kicmm